Maravai LifeSciences Q3 results beat estimates on mRNA products; raises FY outlook
MRVI•Maravai LifeSciences reported Q3 revenue of $45.85 million, up 10% year over year and above the $43.57 million consensus estimate, and adjusted EBITDA of $5.82 million. It raised 2026 revenue guidance to $212 million-$216 million and adjusted EBITDA guidance to $40 million-$42 million.
1. Q3 results
Q3 revenue rose 10% year over year to $45.85 million, beating the $43.57 million consensus estimate. Adjusted EBITDA was $5.82 million, also above consensus, while the company reported a $24 million net loss.
2. Raised outlook
Maravai raised its full-year 2026 revenue guidance to $212 million-$216 million from $205 million-$215 million, and adjusted EBITDA guidance to $40 million-$42 million from $33 million-$35 million. The company said continued demand for Discovery mRNA and GMP consumables is expected to drive growth. mRNA product growth of 28% helped lift TriLink revenue, while Cygnus revenue rose 7.5% on demand for Host Cell Protein and ELISA kits.
